QURE

uniQure's stock experienced significant events in the past six months. On November 3, 2025, the stock plummeted after the FDA questioned the adequacy of AMT-130 data for BLA submission. On March 2, 2026, the stock plunged following the 2025 financial results and a regulatory update for AMT-130, where the FDA recommended a Phase III study. From March 5-10, 2026, public criticism from federal health officials regarding AMT-130 data further impacted the stock, leading to a lawsuit. In April 2026, positive news from a meeting with the UK's MHRA for AMT-130 led to a stock price increase. On May 5, 2026, Q1 2026 earnings beat EPS estimates but missed on revenue, with updates on pipeline programs, including a scheduled Type B FDA meeting for AMT-130, ongoing progress for AMT-260 and AMT-191, and the discontinuation of AMT-162, causing the stock to surge.